Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 15/20 | 0.53 |
| ▸ | METAP2 | P50579 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005393 | 0.93 | ADORA1 (0.47) | ADORA1METAP2POLBAPEX1RECQL | |
| SCHEMBL5005626 | 0.93 | ADORA1 (0.51) | ADORA1METAP2POLBAPEX1RECQL | |
| SCHEMBL5012051 | 0.90 | METAP2 (0.44) | ADORA1METAP2F2POLBMAPT | |
| SCHEMBL5008323 | 0.88 | ADORA1 (0.54) | ADORA1POLBMAPT | |
| SCHEMBL5007715 | 0.85 | MAPT (0.43) | ADORA1METAP2POLBL3MBTL1MAPT | |
| SCHEMBL5007784 | 0.85 | ADORA1 (0.51) | ADORA1POLBMAPT | |
| SCHEMBL5010633 | 0.83 | CLCN2 (0.46) | ADORA1F2POLBAPEX1RECQL | |
| SCHEMBL5005236 | 0.83 | ADORA1 (0.56) | ADORA1POLBL3MBTL1ADORA3MAPT | |
| SCHEMBL5007786 | 0.82 | MAPK14 (0.57) | ADORA1METAP2 | |
| SCHEMBL27637111 | 0.82 | ADORA1 (0.41) | ADORA1METAP2POLBAPEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885METAP2 549/4885F2 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.